Transforming Psoriasis Care with Innovative Therapy
A Novel Therapeutic Approach for Psoriasis Management
Scientific Premise
Targeting the Root of Inflammation
Psoriasis is driven by an overactive immune response, primarily involving the IL-23/IL-17 axis. Traditional therapies often rely on broad immunosuppression or invasive biologics.
Amarani Therapeutics is pioneering non-steroidal, highly localized small-molecule inhibitors designed to penetrate the stratum corneum and neutralize inflammatory targets directly at the site of the plaque.
- Targeted modulation of the IL-17 pathway
- Advanced topical vehicle penetration
- Favorable clinical safety profile
Molecular Simulation
Active Model Grid v4.0
Real-time interactive topography and ligand binding visualization rendering at standard physiological parameters for dermatological application.